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Abstract
Chitosan has been widely used in food industry as a weight-loss aid and a cholesterol-lowering agent. Previous studies have
shown that chitosan affects metabolic responses and contributes to anti-diabetic, hypocholesteremic, and blood glucose-
lowering effects; however, the in vivo targeting sites and mechanisms of chitosan remain to be clarified. In this study, we
constructed transgenic mice, which carried the luciferase genes driven by peroxisome proliferator-activated receptor
(PPAR), a key regulator of fatty acid and glucose metabolism. Bioluminescent imaging of PPAR transgenic mice was applied
to report the organs that chitosan acted on, and gene expression profiles of chitosan-targeted organs were further analyzed
to elucidate the mechanisms of chitosan. Bioluminescent imaging showed that constitutive PPAR activities were detected in
brain and gastrointestinal tract. Administration of chitosan significantly activated the PPAR activities in brain and stomach.
Microarray analysis of brain and stomach showed that several pathways involved in lipid and glucose metabolism were
regulated by chitosan. Moreover, the expression levels of metabolism-associated genes like apolipoprotein B (apoB) and
ghrelin genes were down-regulated by chitosan. In conclusion, these findings suggested the feasibility of PPAR
bioluminescent imaging-guided transcriptomic analysis on the evaluation of chitosan-affected metabolic responses in vivo.
Moreover, we newly identified that downregulated expression of apoB and ghrelin genes were novel mechanisms for
chitosan-affected metabolic responses in vivo.
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Introduction
Chitosan is a polysaccharide comprising copolymers of
glucosamine and N-acetylglucosamine. Chitosan has been used
as a dietary supplement for decreasing the body weight and
lowering the cholesterol level [1]. It is a food additive and can be
used as a flocculant and chelating agent for the clarification of
beverages [2]. It is also a biodegradable carbohydrate polymer
that has been widely used in the tissue engineering, wound healing,
biosensers, and drug release [3–8]. Previous reports showed that
chitosan exhibits anti-diabetic, hypocholesteromic, and blood
glucose-lowering effects [9–11]. In vitro studies also suggested that
chitosan inhibits adipogenesis and differentiation of adipocytes
[12,13]. However, the host response to chitosan and the target
organs chitosan acted on remain to be clarified.
Peroxisome proliferator-activated receptors (PPARs) are mem-
bers of the nuclear hormone receptor superfamily. PPAR
heterodimerizes the retinoid X receptors and binds to the PPAR
responsive element (PPRE) in the promoter region of target genes
[14,15]. So far, three receptor subtypes have been characterized
and designated as PPARa, PPARc, and PPAR-b/d. PPAR
subtypes have distinct tissue localization and physiological
activities. PPARa is expressed in brain and liver. It is a central
regulator of fatty acid catabolism and glucose metabolism [16].
PPARc is predominately expressed in adipose tissue, immune
system, and gastrointestinal tract. It is the master regulator of
adipogenesis, adipocyte and gut epithelial differentiation, lipid
storage, and glucose homeostasis [17]. PPAR-b/d is ubiquitously
expressed and plays an important role in regulating energy
homeostasis and lipoprotein catabolism [18]. These findings
indicate that PPARs are key regulators of lipid and glucose
metabolism [19,20].
We have previously applied nuclear factor-kB bioluminescent
imaging-guided transcriptomic analysis to assess host responses to
biomaterials, ionizing radiation, and chemotherapy drug in vivo
[21–23]. In this study, we applied PPAR bioluminescent imaging
to evaluate the chitosan-affected metabolic responses. Microarray
analysis of chitosan-targeted organs was further applied to globally
elucidate gene expression profiles of chitosan and to find the novel
mechanisms of chitosan. Our data showed that chitosan activated
PPAR activities in brain and stomach. Additionally, chitosan
regulated several pathways involved in lipid and glucose
metabolism, which was in agreement with the well-known
hypocholesterolemic and hypoglycemic effects of chitosan.
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Plasmid construction
The 148-bp EcoRI/XhoI fragment containing the herpes
simplex virus thymidine kinase (tk) promoter from pTKb (Clontech,
Mountain View, CA, USA) was ligated into the EcoRI/XhoI sites of
the pBluescriptH II KS (-) vector (Stratagene, La Jolla, CA, USA)
to generate pBKS-Ptk. Two oligonucleotides, PPRE sense (59-
TCGACAGGGGACCAGGACAAAGGTCACGTTCGGGAC-
39) and PPRE antisense (59-TCGAGTCCCGAACGT-
GACCTTTGTCCTGGTCCCCTG-39) containing the PPRE
sequence of the acyl-CoA oxidase gene and carrying the SalI
and XhoI restriction sites at the ends, were annealed and ligated to
form two (72 bp), three (108 bp), four (144 bp), five (180 bp), six
(216 bp), seven (252 bp), and eight (288 bp) tandem repeats of
PPRE. The PPRE tandem repeats were then filled in and inserted
into the blunted XbaI site of the pBKS-Ptk vector to generate
pBKS-PPRE2x-Ptk, pBKS-PPRE3x-Ptk, pBKS-PPRE4x-Ptk,
pBKS-PPRE5x-Ptk, pBKS-PPRE6x-Ptk, pBKS-PPRE7x-Ptk, and
pBKS-PPRE8x-Ptk. The SmaI/BglII fragments containing the tk
promoter and/or PPRE repeats from aforementioned constructs
were then subcloned into the SmaI/BglII sites of the pGL2-Basic
vector (Promega, Madison, WI, USA) to generate pGL-PPRE0x-
Ptk, pGL-PPRE2x-Ptk, pGL-PPRE3x-Ptk, pGL-PPRE4x-Ptk,
pGL-PPRE5x-Ptk, pGL-PPRE6x-Ptk, pGL-PPRE7x-Ptk, and
pGL-PPRE8x-Ptk (Figure 1(A)).
Transfection and reporter assays
Human hepatocellular carcinoma HepG2 cells, which were
purchased from Bioresource Collection and Research Center
(Hsinchu, Taiwan), were maintained in Dulbecco’s modified
Eagle’s medium (Life Technologies, Gaithersburg, MD, USA)
supplemented with 10% fetal bovine serum at 37uC. Cells were
transfected with PPRE reporter constructs and pcDNA3.1/lacZ
DNA (Invitrogen, Carlsbad, CA, USA) by SuperFectH transfection
reagent (Qiagen, Valencia, CA, USA). Twenty-four hours later,
transfected cells were treated with 0.5 mM rosiglitazone maleate
(Alexis, San Diego, CA, USA). Luciferase assay and b-galactosi-
dase assay were performed as described previously [24,25].
Induction fold was calculated by dividing the relative luciferase
unit (RLU) of rosiglitazone-treated cells by the RLU of untreated
cells.
Generation of transgenic mice
Plasmid DNA pGL-PPRE5x-Ptk was linearized with NotI and
SalI to generate a 3.1-kb fragment of PPRE transgene for the
generation of transgenic mice following pronuclear microinjection
of FVB oocytes. Of 18 offspring (F0), six tested positive for PPRE
transgene by polymerase chain reaction (PCR) genotyping
(primer-P 59-AACTGCATAAGGCTATGAAGAGA-
TACGCCC-39 and primer-M 59-TTAAAACCGGGAGGTA-
GATGAGATGTGACG-39). All transgenic mice were crossed
with wild-type F1 mice to yield PPRE heterozygous mice with the
FVB genetic background.
Animal experiments
Male transgenic mice (6 to 8 weeks old) were maintained in the
room with a 12-h day/12-h night cycle and fed with standard diet
ad libitum. Mice (n=6/group) were subcutaneously injected saline
or 0.2 g/kg chitosan. Chitosan oligosaccharide lactate
(MW=4000–6000, .90% deacetylation) was purchased from
Sigma-Aldrich (St. Louis, MO, USA) and dissolved in DDW. For
rosiglitazone treatment, six mice were orally administered 50 mg/
kg rosiglitazone. Mice were then imaged for the luciferase activity
or sacrificed for microarray analysis at indicated periods.
Mouse experiments were conducted under ethics approval from
the China Medical University Animal Ethics Committee (permit
number 97-28-N).
In vivo and ex vivo imaging of luciferase activity
In vivo and ex vivo imaging of luciferase activity was performed as
described previously [24,26]. For in vivo imaging, mice were
anesthetized with isoflurane and injected intraperitoneally
150 mg/kg D-luciferin. Five minutes later, mice were placed in
the chamber and imaged for 1 min with the camera set at the
highest sensitivity by IVIS Imaging SystemH 200 Series (Xenogen,
Hopkinton, MA, USA). Photons emitted from tissues were
quantified using Living ImageH software (Xenogen). Signal
intensity was quantified as the sum of all detected photon counts
from mice and presented as photon/sec. For ex vivo imaging, mice
were anesthetized and injected with luciferase intraperitoneally.
Five minutes later, mice were sacrificed and tissues were rapidly
removed. Tissues were placed in the IVIS system and imaged with
the same setting used for in vivo studies. Signal intensity was
quantified as the sum of all detected photon counts per second
within the region of interest after subtracting the background
luminescence and presented as photon/sec/cm
2/steradian (pho-
ton/sec/cm
2/sr).
Microarray analysis
Total RNAs were extracted from brain and stomach as
described previously [25]. The RNA sample with a RNA integrity
number greater than 7.0 was accepted for microarray analysis.
Microarray analysis was performed as described previously [25].
Briefly, fluorescence-labeled RNA targets were prepared from
5 mg of total RNA using MessageAmp
TM aRNA kit (Ambion,
Austin, TX, USA) and Cy5 dye (Amersham Pharmacia, Piscat-
away, NJ, USA). Fluorescent targets were hybridized to the Mouse
Whole Genome OneArray
TM (Phalanx Biotech Group, Hsinchu,
Taiwan) and scanned by an Axon 4000 scanner (Molecular
Devices, Sunnyvale, CA, USA). Three replicates from three
independent mice were performed. The Cy5 fluorescent intensity
of each spot was analyzed by genepix 4.1 software (Molecular
Devices). The signal intensity of each spot was corrected by
subtracting background signals in the surrounding. We filtered out
spots that signal-to-noise ratio was less than 0 or control probes.
Spots that passed these criteria were normalized by the R program
in the limma package (http://www.r-project.org/). Genes with
fold changes $2.0 or #22.0 were analyzed by Kyoto Encyclo-
pedia of Genes and Genomes (KEGG) pathway (http://www.
genome.ad.jp/kegg/), which is a knowledge base linking a set of
genes with a network of interacting molecules in the cells [27]. We
used the WebGestalt tool to test significant KEGG pathways.
Microarray data are MIAME compliant and the raw data have
been deposited in a MIAME compliant database (Gene Expres-
sion Omnibus, accession number GSE33565).
Quantitative real-time PCR (qPCR)
The expression levels of ghrelin, apolipoprotein B (apoB),
exportin 4 (xpo4), peptidyl-prolyl cis/trans isomerase NIMA-
interacting 1 (pin1), preproenkephalin 1 (penk1), and peroxir-
edoxin 2 (prdx2) genes were validated by qPCR. RNA samples
were reverse-transcribed for 2 h at 37uC with High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, Foster
City, CA, USA). qPCR was performed by using 1 ml of cDNA, 26
SYBR Green PCR Master Mix (Applied Biosystems), and 200 nM
of forward and reverse primers. The reaction condition was
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at 60uC. Each assay was run on an Applied Biosystems 7300 Real-
Time PCR system in triplicates. Fold changes were calculated
using the comparative CT method. The primer set for each gene is
followed: ghrelin forward, 59-GCTGGAGATCAGGTTCAAT
GC-39; ghrelin reverse, 59-GTCCGTGGTTACTTGTCAGC-39;
apoB forward, 59-TCTGCCTCTTACTACCCACTG-39; apoB
reverse, 59-TGTCAACCAAAGACTTGTCCTC-39; xpo4 for-
Figure 1. Construction and optimization of PPRE reporter constructs. (A) The schematic diagram of PPRE reporter constructs. Two PPRE
oligonucleotides were annealed and ligated to form various tandem repeats of PPRE. The resulting products were analyzed by 8% polyacrylamide
gels (left panel). Eight reporter constructs containing various numbers of PPREs were shown on the right. (B) Effect of rosiglitazone on the inducibility
of PPRE reporter constructs. HepG2 cells were transiently transfected with PPRE constructs and pcDNA3.1/lacZ DNA, and treated without or with
0.5 mM rosiglitazone. Luciferase and b-galactosidase activities were determined 24 hours later. Luciferase activities are expressed as induction fold,
which is presented as comparison with RLU related to untreated cells. b-Galactosidase activities are expressed as OD420. Values are mean 6 standard
error of three independent assays. **p,0.01, ***p,0.001, compared with untreated cells. (C) In vitro imaging. HepG2 cells were transiently
transfected with PPRE constructs containing 5 tandem repeats of PPRE and treated without or with 0.5 mM rosiglitazone. Luciferase activity was
imaged at 24 h by IVIS system. The color overlay on the image represents the photon/sec emitted from the cells, as indicated by the color scale.
Quantification of photon emission from the cells was shown at the bottom. Values are mean 6 standard error of three independent assays.
***p,0.001, compared with mock. Photos are representative images.
doi:10.1371/journal.pone.0034969.g001
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GTGGTCATCTCCGTGTTGTG-39; pin1 forward, 59-ATGGC
GGACGAGGAGAAG-39; pin1 reverse, 59- CGAGACTGGCT
GTGCTTC-39; penk1 forward, 59-CTTGGGTCCTGCCTCC
TG-39; penk1 reverse, 59-GCAAGTGGCTCTCATCCTG-39;
prdx2 forward, 59-CGACCATGCTGAGGACTTC-39; prdx2
reverse, 59- TCAACACGCCGTAATTCTGG-39; glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) forward, 59-ACACC-
CACTCCTCCACCTTT-39; GAPDH reverse, 59-TAGCCAAA
TTCGTTGTCATACC-39.
Statistical analysis
Data were presented as mean 6 standard error. Student’s t-test
was used for comparisons between two experiments. A value of
p,0.05 was considered statistically significant.
Results
Optimization of PPRE reporter constructs
Multiple tandem repeats of PPRE were constructed and cloned
upstream the tk promoter. The resulting PPRE-tk constructs were
then inserted upstream the luciferase gene and droven the
expression of luciferase gene (Figure 1(A)). To test which report
constructs were significantly induced by rosiglitazone (a PPARc
agonist), we transiently transfected HepG2 cells with various
reporter constructs and treated cells with rosiglitazone. As shown
in Figure 1(B), rosiglitazone significantly induced the luciferase
activity driven by five, six, seven, or eight tandem repeats of
PPRE. The maximal induction was observed in HepG2 cells
transfected with five or six tandem repeats of PPRE construct. The
b-galactosidase activities were consistent, suggesting that the
transfection efficacies were similar in various reporter constructs.
Moreover, in vitro imaging showed that bioluminescent signal was
significantly induced by rosiglitazone in pGL-PPRE5x-Ptk-trans-
fected HepG2 cells (Figure 1(C)). Ciani et al. constructed the
luciferase reporter plasmids containing one, two, three, and five
tandem repeats of PPRE, and found that the induced luciferase
activity is directly proportional to the number of PPREs present in
the promoter region [28]. However, the maximal induction of
luciferase activity was observed in HepG2 cells transfected with
five or six tandem repeats of PPRE construct in this study.
Therefore, we selected the construct containing five tandem
repeats of PPRE for further experiment, and these findings
suggested that induced luciferase activity might not be propor-
tional to the number of PPREs.
Characterization of PPRE transgenic mice
Plasmid DNA pGL-PPRE5x-Ptk was selected for the generation
of transgenic mice following pronuclear microinjection of FVB
oocytes. Because the transgene contained a luciferase gene driven
by PPRE, the luciferase activity reflected the PPAR trans-activity.
To monitor the constitutive and induced PPAR activity,
transgenic mice were treated without or with rosiglitazone and
imaged 6 hours later. As shown in Figure 2(A), the diffuse
luminescence was detected throughout the body and the intense
signals were emitted in the head and abdominal region.
Administration of rosiglitazone significantly induced the PPAR-
dependent luminescent signals in mice. Ex vivo imaging showed
that the maximal intensity was observed in the brain, moderate
luminescent signals were observed in liver and stomach, and slight
intensity was observed in heart, lung, spleen, kidney, and intestine
(Figure 2(B)). Administration of rosiglitazone increased the PPAR-
dependent luminescent intensity in brain and stomach. These data
indicated that endogenous PPAR activities were widely present in
most organs and the greater endogenous PPAR activities were
observed in brain, liver, and stomach. Moreover, rosiglitazone
activated the PPAR activities in the brain and stomach, which was
consistent with previous studies [28], suggesting that PPRE
transgenic mice could be applied to report the PPAR activity in
vivo.
Assessment of PPAR-driven luminescent signal after
chitosan administration by bioluminescent imaging
Previous studies have shown that chitosan activates the PPAR
activity in adipocytes [13]. We further analyzed the in vivo PPAR
activity after chitosan administration and the targeted organs that
chitosan acted on by bioluminescent imaging. Figure 3(A) shows
that chitosan gradually increased the luminescence intensity,
reached a maximal intensity on 3 d, and gradually decreased the
luminescent signals. We further sacrificed mice on 3 d after
administration, and ex vivo imaging showed that chitosan
significantly induced PPAR-dependent bioluminescent signals in
brain (1.75 fold) and stomach (2.54 fold) (Figure 3(B)). These
findings indicated that administration of chitosan activated PPAR
activities in brain and stomach.
Assessment of chitosan-regulated genes in the brain and
stomach by transcriptomic analysis
In order to understand the chitosan-induced biological events in
brain and stomach, we extracted RNA samples from brain and
stomach on 3 d and performed microarray analysis. In a total of
29,922 genes, the transcripts of 154 and 143 genes in the stomach
and brain, respectively, passed the aforementioned criteria (Table
S1 and Table S2) and selected for KEGG classification. Tables 1
and 2 show the pathways significantly regulated by chitosan in the
stomach and brain, respectively. Five pathways, including
oxidative phosphorylation, ribosome, GnRH signaling pathway,
tumor necrosis factor-a (TNF-a) signaling pathway and insulin
signaling pathway, were affected commonly by chitosan in both
organs, and oxidative phosphorylation and ribosome pathways
were the top two pathways affected by chitosan. The majority of
pathways, including oxidative phosphorylation, pyruvate metab-
olism, GnRH signaling pathway, glycolysis/gluconeogenesis,
benzoate degradation, glycerolipid metabolism, ether lipid metab-
olism, glutathione metabolism, insulin signaling pathway, alanine
and aspartate metabolism and IGF signaling pathway, were
associated with lipid and glucose metabolism. These data showed
that chitosan might alter several pathways involved in lipid and
glucose metabolism in brain and stomach.
Verification of the expression levels of chitosan-regulated
genes by qPCR
To elucidate which PPAR subtype contributed to the chitosan-
affected gene expression profile, we performed Pscan to analyze
the PPRE in the promoter regions of chitosan-regulated genes.
Pscan is a software that scans promoter sequences of genes with
motifs describing the binding specificity of known transcription
factors [29]. Over the half of genes contained PPAR-a and/or
PPAR-c responsive elements in their promoter regions, suggesting
that the majority of genes were regulated by chitosan via PPAR-a
and/or PPAR-c signaling pathways (data not shown). PPAR-a
and PPAR-c-regulated genes were further validated by qPCR.
The expression levels of PPAR-c-regulated genes, xpo4 and
penk1, and PPAR-a-regulated genes, pin1 and prdx2, were
upregulated by chitosan in the stomach and brain, which were in
agreement with microarray data (Table 3). These data suggested
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e34969Figure 2. PPAR-dependent bioluminescence in living mice and individual organs. (A) In vivo imaging. Transgenic mice were orally
administered saline (mock) or 50 mg/kg rosiglitazone and imaged 6 hours later. The color overlay on the image represents the photon/sec emitted
from the animals, as indicated by the color scales. Quantification of photon emission from the mice was shown at the bottom. Values are mean 6
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e34969standard error (n=6 per group). *p,0.05, **p,0.01, compared with mock. (B) Ex vivo imaging. Transgenic mice were orally administered saline
(mock) or 50 mg/kg rosiglitazone. Six hours later, mice were sacrificed and organs were subjected to image. Quantification of photon emission from
the organs was shown at the bottom. Values are mean 6 standard error (n=6 per group). Photos are representative images.
doi:10.1371/journal.pone.0034969.g002
Figure 3. PPAR-dependent bioluminescence in living mice and individual organs after chitosan administration. (A) Time course.
Transgenic mice were subcutaneously injected saline (mock) or chitosan, and images at indicated periods. Results are expressed as relative intensity,
which is presented as comparison with the luminescent intensity relative to mock. Values are mean 6 standard error (n=6 per group). (B) Ex vivo
imaging and quantification of photon emission from individual organs. Transgenic mice were subcutaneously injected saline (mock) or chitosan, and
sacrificed 3 days later for organ imaging. Values are mean 6 standard error (n=6 per group). *p,0.05, ***p,0.001, compared with mock. The color
overlay on the image represents the photon/sec emitted from the organs, as indicated by the color scale. Photos are representative images.
doi:10.1371/journal.pone.0034969.g003
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PPAR-c signaling pathways.
Ghrelin and apoB are expressed in the stomach and have been
shown to be involved in energy and lipid metabolism [30,31].
Microarray data showed that the expressions of ghrelin and apoB
genes were downregulated by chitosan in the stomach, with fold
changes of 29.1360.03 and 25.5060.25, respectively (Table S1
and Table S2). We further applied qPCR to validate the
transcriptional expression levels of these genes. As shown in
Table 3, the expression levels of ghrelin and apoB genes were
down-regulated by chitosan, which was consistent with the
microarray data.
Discussion
In this study, we found that chitosan significantly activated
PPAR activity in brain and stomach. Microarray analysis of brain
and stomach further showed that several pathways involved in
glucose and lipid metabolism were affected by chitosan. PPARs
are ligand-activated nuclear receptors and key regulators of fatty
acid and glucose homeostasis [19,20]. In vivo and ex vivo imaging
showed that maximal luciferase activities were detected in brain
and gastrointestinal tract. These data suggested that PPARs were
highly expressed in these organs. Previous studies have shown that
PPAR activities are activated in brain and gastrointestinal tract,
and their activation play important roles in these organs. For
examples, in the brain, PPARa plays a major role in acetylcholine
biosynthesis and defense against oxidative stress, PPARc regulates
the action of dopamine on the gene transcription, and PPARb/d
transcriptionally upregulates the acyl-CoA synthetase 2 and
mediates the fatty acid utilization [32]. Additionally, the
constitutive expression of PPARb/d in the gastrointestinal tract is
very high compared with other tissues. It plays physiological roles
in the homeostatic regulation of intestinal cell proliferation/
differentiation and the modulation of inflammation associated with
inflammatory bowel disease and colon cancer [33]. Ciani et al
(2007) constructed PPAR-luciferase transgenic mice with C57BI/6
genetic background and showed that maximal luciferase activity
was detected in the brain and gastrointestinal tract [28]. In this
study, we found that PPAR-driven luminescent intensity was
strong in the brain and stomach, which was in agreement with
previous study. Therefore, these findings suggested that biolumi-
nescent imaging of PPAR transgenic mice was capable of
reflecting the real-time PPAR activity in living animals.
Chitosan is a nontoxic, antibacterial, biodegradable, and
biocompatible biopolymer. It has been widely used in food and
biomaterial industries as weight-loss aids, cholesterol-lowering
agents, and medical devices, such as bio-scaffolds for tissue
engineering, wound healing products, and haemostatic bandages
[1,3–8]. Although chitosan is usually administered by an oral route
as a dietary supplement, food additive, or oral drug delivery,
chitosan would be degraded by gut microflora or influence the
distribution and number of gut microflora by oral administration
[1,2,34]. Therefore, we administered transgenic mice with
chitosan by a parenteral route to avoid the influence of gut
microflora. Chitosan induced a maximal intensity on 3 d, and the
signal gradually decreased after three days, suggesting that
subcutaneous administration of chitosan evoked the PPAR
activity, and the induced PPAR activity was decreased to the
basal level after 3 days. Administration of chitosan evoked PPAR
activations in brain and stomach. These findings suggested that
chitosan might affect the biological events in brain and stomach. It
Table 1. Classification of chitosan-regulated genes in the
stomach by KEGG pathways.
KEGG pathway Stomach
Observed (total)
a p value
b
Oxidative phosphorylation 38 (108) 8.75610
211
Ribosome 20 (80) 2.17610
28
Cell communication 21 (109) 6.11610
25
IL6 signaling pathway 4 (29) 0.0037
Pyruvate metabolism 11 (37) 0.0040
GnRH signaling pathway 14 (90) 0.0105
TNF-a signaling pathway 3 (34) 0.0105
Glycolysis/Gluconeogenesis 14 (53) 0.0107
Benzoate degradation 2 (7) 0.0215
Glycerolipid metabolism 9 (46) 0.0215
IFNc signaling pathway 11 (65) 0.0215
LPS signaling pathway 11 (66) 0.0215
Ether lipid metabolism 6 (29) 0.0249
Wnt signaling pathway 14 (144) 0.0325
Glutathione metabolism 9 (41) 0.0363
IL12 signaling pathway 4 (26) 0.0476
Insulin signaling pathway 8 (91) 0.0476
a‘‘Observed’’ means the number of genes regulated by chitosan in this pathway.
‘‘Total’’ means the total number of genes in this pathway.
bp-Value was calculated on WebGestalt web site (http://bioinfo.vanderbilt.edu/
webgestalt/login.php) by hypergeometric test.
doi:10.1371/journal.pone.0034969.t001
Table 2. Classification of chitosan-regulated genes in the
brain by KEGG pathways.
KEGG pathway Brain
Observed (total)
a p value
b
Oxidative phosphorylation 25 (108) 5.94610
26
Ribosome 22 (80) 4.49610
27
Amyotrophic lateral sclerosis 3 (17) 0.0117
Gas6 signaling pathway 4 (18) 0.0117
Long-term depression 16 (73) 0.0117
TNF-a signaling pathway 7 (34) 0.0117
PDGF signaling pathway 4 (27) 0.0130
Gap junction 16 (81) 0.0258
Long-term potentiation 14 (64) 0.0258
GnRH signaling pathway 15 (90) 0.0345
Regulation of actin cytoskeleton 22 (193) 0.0345
Insulin signaling pathway 11 (91) 0.0359
Alanine and aspartate metabolism 3 (30) 0.0416
EGF signaling pathway 9 (41) 0.0416
Tight junction 17 (112) 0.0416
Regulation of Ck1/Cdk5 3 (9) 0.0416
IGF signaling pathway 8 (54) 0.0452
a‘‘Observed’’ means the number of genes regulated by chitosan in this pathway.
‘‘Total’’ means the total number of genes in this pathway.
bp-Value was calculated on WebGestalt web site (http://bioinfo.vanderbilt.edu/
webgestalt/login.php) by hypergeometric test.
doi:10.1371/journal.pone.0034969.t002
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pathogenesis of various disorders of central nervous system. For
examples, activation of PPARs suppresses inflammation in
peripheral macrophages and in models of human autoimmune
diseases [35]. Activation of all PPAR isoforms has been found to
be protective in murine models of multiple sclerosis, Alzheimer’s
disease, and Parkinson’s diseases [36,37]. In this study, ex vivo
imaging showed that chitosan activated the PPAR activity in the
brain and the KEGG pathway analysis showed that chitosan
significantly regulated the expression of genes involved in
amyotrophic lateral sclerosis (p=0.012). These findings suggested
that chitosan might exhibit the beneficial effect on the neurode-
generative diseases, such as multiple sclerosis, Alzheimer’s disease,
and Parkinson’s diseases.
In addition to brain, chitosan also evoked the PPAR activity in
the stomach. KEGG pathway analysis further revealed that the
half of chitosan-regulated pathways in the stomach was related to
glucose or lipid metabolism. It has been shown that chitosan and
its derivatives markedly prevent the time course-related rise of
serum glucose levels in diabetic mice [38]. Moreover, chitosan is
well known for its hypotriglyceridemic and hypocholesterolemic
effects [39], and exhibits anti-obesity and anti-diabetic effects [1,9–
11]. Previous studies showed that chitosan and its derivatives may
bind to bile salt components and free fatty acids, resulting in the
disrupted lipid absorption in the gut and the increased faecal fat
excretion [40]. Chitosan also downregulates the adipogenic
molecules such as fatty acid binding protein and glucose
transporter 4 via PPAR and CCAAT/enhancer-binding protein
a pathways, resulting in the inhibited adipogenesis and differen-
tiation of 3T3-L1 adipocytes [12,13]. Additionally, plasma
proteome analysis showed that chitosan increases the level of
adiponectin and decreases the levels of obesity-related proteins,
such as resistin, retinol-binding protein 4, TNF-a and interleukin-
6 (IL-6), contributing to the anti-diabetic and anti-obesity
potentials in ob/ob mice [10]. Our data showed that chitosan
significantly regulated the IL-6 and TNF-a signaling pathways in
the guts, which were consistent with previous findings. Moreover,
we newly identified that chitosan significantly regulated the
glucose metabolic pathways, such as glycolysis/gluconeogenesis
and insulin signaling pathway, which might contribute to the
hypoglycemic effect of chitosan.
Microarray data showed that chitosan downregulated the
expressions of apoB and ghrelin genes in the stomach. ApoB, a
large amphipathic protein, is mainly expressed in the liver and is
present on very-low density lipoproteins (VLDL), intermediate
density lipoproteins, and low-density lipoproteins. ApoB is
required for the formation of VLDL in the liver. Binding of apoB
to the microsomal transport protein results in the incorporation of
lipids into the apoB molecule and leads to the formation of VLDL
particles [30,41]. In clinical practice, apoB can be used as a
marker to estimate the total number of atherogenic lipoprotein
particles [42]. Elevated apoB is a hallmark of several inherited
disorders associated with atherosclerosis [43]. However, patients
with extremely low levels of apoB seem to be protected against
cardiovascular diseases [44]. Because apoB is an essential
component of lipoprotein, the down-regulated expression of apoB
gene by chitosan might contribute to the hypotriglyceridemic and
hypocholesterolemic effects of chitosan. Ghrelin is a peptide
hormone mainly produced by the stomach. Ghrelin is a potent
stimulator of growth hormone secretion [45]. Moreover, it is the
only circulatory hormone that potently enhances the feeding and
weight gain, increases the gastrointestinal mobility, and regulates
Table 3. Expression levels of ghrelin, apoB, xpo4, pin1, penk1, and prdx2 genes by qPCR.
Sample
a Average CT of target Average CT of GAPDH DCT
b DDCT
c Relative to mock
Ghrelin
Mock 17.7760.02 17.5660.02 0.2160.03 0.0060.03 1.00
Chitosan 21.2060.02 17.5760.01 3.6360.02 3.4260.02 0.09
ApoB
Mock 26.1460.02 17.5660.02 8.5860.03 0.0060.03 1.00
Chitosan 29.0260.05 17.5760.01 11.4560.05 2.8660.05 0.13
Xpo4
Mock 27.2060.11 18.5660.10 8.6460.15 0.0060.15 1.00
Chitosan 26.8160.07 18.9360.05 7.8860.09 20.7660.09 1.70
Pin1
Mock 24.1160.02 18.5660.10 5.5460.10 0.0060.10 1.00
Chitosan 24.0460.04 18.9360.05 5.1160.07 20.4360.07 1.35
Penk1
Mock 25.0760.04 18.3960.04 6.6860.06 0.0060.06 1.00
Chitosan 22.3660.06 17.7660.10 4.6060.12 22.0860.12 4.23
Prdx2
Mock 22.0060.00 18.3960.04 3.6160.04 0.0060.04 1.00
Chitosan 20.2560.07 17.7660.10 2.4960.12 21.1260.12 2.18
aThe RNAs from stomach (ghrelin, apoB, xpo4, and pin1 genes) and brain (penk1 and prdx2 genes) were analyzed for indicated genes by qPCR.
bThe DCT value is determined by subtracting the average CT of GAPDH from that of target gene. The standard deviation of the difference is calculated from the standard
deviations of the target gene and GAPDH.
cThe calculation of DDCT involves subtraction by the DCT calibrator value. This is a subtraction of an arbitrary constant, so the standard deviation of DDCT is the same as
the standard deviation of the DCT value.
doi:10.1371/journal.pone.0034969.t003
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components may have therapeutic effects in treating malnutrition
[31]. Because ghrelin has a great impact on the food intake or
body weight, the down-regulated expression of ghrelin gene by
chitosan might explain why chitosan exhibited the anti-obestic
effect.
In conclusion, we applied PPAR bioluminescent imaging-
guided transcriptomic analysis to evaluate the organs that chitosan
acted on and to analyze the molecular mechanisms of chitosan in
this study. We found that administration of chitosan induced the
PPAR-driven bioluminescent signals in brain and stomach.
Microarray analysis showed that several pathways associated with
lipid and glucose metabolism were regulated by chitosan.
Moreover, we newly identified that chitosan may exhibit
hypocholestemic and anti-obestic effects via downregulated
expression of apoB and ghrelin genes. These findings suggested
the feasibility of PPAR bioluminescent imaging-guided transcrip-
tomic analysis on the evaluation of chitosan-affected metabolic
responses in vivo. Moreover, we newly identified that downregu-
lated expression of apoB and ghrelin genes were the novel
mechanisms for chitosan-affected metabolic responses in vivo.
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